Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Asahi Kasei Pharma Exec Hori Picked as Next President
March 10, 2014
- Takeda Submits NDA for Once-Weekly DPP-4 Inhibitor Trelagliptin
March 10, 2014
- US Journal to Revise COI Disclosure in Article Used by Shionogi and Eli Lilly Japan to Promote Cymbalta
March 10, 2014
- 28% of Mainstays to Face New Price Cuts for Long-Listed Drugs: Jiho Survey
March 7, 2014
- Map Software Used to Reorganize MRs’ Marketing Territories Boosts Operating Efficiency at Pfizer Japan
March 7, 2014
- Five Generic Makers See Various Price Reduction Rates under FY2014 NHI Revision
March 6, 2014
- New Price Cuts for Long-Listed Drugs to Pummel MTPC, Astellas: Jiho Tally
March 6, 2014
- Santen Licenses Anti-Endoglin Antibodies from TRACON to Develop Novel Treatments for Retinal Diseases
March 6, 2014
- Samsca Tops January “Mind Share” Ranking in HP Market
March 5, 2014
- Eylea Filed for Diabetic Macular Edema in Japan: Bayer HealthCare
March 5, 2014
- Takeda Extended 3.7 Billion Yen in CASE-J-Linked Grants to Kyoto Univ., 2 Entities; “No COI” Says Pres. Hasegawa
March 4, 2014
- Takeda Apologizes for Violating Promotion Code, Inappropriate Expressions in Ads
March 4, 2014
- DSP Transfers Marketing Rights for Inteban, Catlep, and Drenison to Teikoku Seiyaku
March 4, 2014
- Astellas Secures Exclusive Rights for Isavuconazole in US, Canada
March 4, 2014
- Dnavec, NCGM, Nippon Zenyaku to Codevelop Drug Discovery Tool for Anti-Obesity Treatment
March 3, 2014
- Takeda Files NDA for Promising Acid-Related Disease Drug in Japan
March 3, 2014
- Novartis Files for Approval of Exforge OD Tablets
March 3, 2014
- Takeda’s Next Leader Weber to Take Up COO Role on April 1
March 3, 2014
- Mizuho Projects 5% Upswing for FY2014 Operating Profit of 9 Major Japan Pharmas
February 28, 2014
- Nipro Opens Sales Subsidiary in Sweden
February 28, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…